Taking a daily supplement made from fruits and vegetables like pomegranate and turmeric can slow down the rise of a cancer marker called PSA in men with slow-growing prostate cancer, which might help them avoid harsh treatments.
Scientific Claim
A phytochemical-rich food supplement containing standardized extracts of ginger, cranberry, pomegranate, turmeric, broccoli, and green tea reduces the rate of PSA progression by 13.4% in men with indolent prostate cancer over 16 weeks, suggesting a potential role in slowing disease progression during active surveillance.
Original Statement
“For the 105 men on PRS+P, the average rate of PSA rise pre to post baseline changed from 19.6% to 6.2% - a statistically significant (SS) reduction of 13.4% (a paired t-test p<0.01).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
Although the study is an RCT, the abstract does not fully confirm blinding success or randomization allocation concealment. Therefore, definitive verbs are inappropriate; 'reduces' should be tempered to probabilistic language consistent with EBM guidelines.
More Accurate Statement
“A phytochemical-rich food supplement containing standardized extracts of ginger, cranberry, pomegranate, turmeric, broccoli, and green tea may reduce the rate of PSA progression by 13.4% in men with indolent prostate cancer over 16 weeks, suggesting a potential role in slowing disease progression during active surveillance.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether this specific phytochemical supplement consistently reduces PSA progression across multiple RCTs in diverse populations with indolent prostate cancer.
Whether this specific phytochemical supplement consistently reduces PSA progression across multiple RCTs in diverse populations with indolent prostate cancer.
What This Would Prove
Whether this specific phytochemical supplement consistently reduces PSA progression across multiple RCTs in diverse populations with indolent prostate cancer.
Ideal Study Design
A meta-analysis of at least 5 high-quality, double-blind, placebo-controlled RCTs (each n≥150) evaluating identical phytochemical supplements (same extracts, doses, duration) in men aged 65–80 with confirmed indolent prostate cancer on active surveillance, using PSA velocity as the primary endpoint over 12–24 months.
Limitation: Cannot establish biological mechanisms or long-term clinical outcomes like metastasis or survival.
Randomized Controlled TrialLevel 1bIn EvidenceCausal effect of the supplement on PSA progression compared to placebo in a larger, longer-term population with clinical endpoints.
Causal effect of the supplement on PSA progression compared to placebo in a larger, longer-term population with clinical endpoints.
What This Would Prove
Causal effect of the supplement on PSA progression compared to placebo in a larger, longer-term population with clinical endpoints.
Ideal Study Design
A double-blind, placebo-controlled RCT of 500 men aged 65–80 with indolent prostate cancer, randomized to receive the same phytochemical supplement or placebo for 24 months, with primary outcome of PSA velocity and secondary outcomes of time to intervention, MRI changes, and quality of life.
Limitation: Cannot prove long-term survival benefit or impact on metastatic transformation without decades of follow-up.
Prospective Cohort StudyLevel 2bLong-term association between supplement use and reduced risk of disease progression or need for radical treatment in real-world settings.
Long-term association between supplement use and reduced risk of disease progression or need for radical treatment in real-world settings.
What This Would Prove
Long-term association between supplement use and reduced risk of disease progression or need for radical treatment in real-world settings.
Ideal Study Design
A prospective cohort of 1,000 men with indolent prostate cancer on active surveillance, tracking daily supplement intake (including this formulation) over 5 years, with annual PSA, MRI, and biopsy data to assess progression to active treatment.
Limitation: Cannot rule out confounding by lifestyle, diet, or adherence differences.
Evidence from Studies
Supporting (1)
This study gave men with slow-growing prostate cancer a supplement with ginger, turmeric, and other plant extracts, and found their PSA levels rose much slower—exactly what the claim says. It’s a high-quality trial, so the result is reliable.